Metastatic liver disease is one of the most common causes of death in cancer patients. Complete surgical resection is currently considered the only curative treatment, with only about 25% of patients being amenable to surgery.
Liver cancer incidence are rising, for a plethora of reasons including viral infections and lifestyle. Primary liver cancer is a challenging condition to diagnose and treat, in part because many cases of liver cancer are diagnosed when the condition is already advanced or surgical treatment are no longer an option.
A company we have discovered DCTH (Delcath Systems, Inc.), has a fascinating treatment for liver cancer. The company has initiated a global Phase 3 clinical trial for patients with intrahepatic cholangiocarcinoma (ICC), using its drug product Melphalan/HDS. DCTH reported that the FDA has approved the design of this phase 3 clinical trial using their Melphalan/HDS drug product under what is called a Special Protocol Assessment. If this is the first time you are hearing about DCTH, start doing your own due diligence right away. DCTH is a very interesting biotechnology company, that seems to be very undervalued in our opinion, and totally under the radar currently. DCTH has a market cap of under two million dollars, for a company with a drug closing in on a phase 3 clinical trial this seems quite low. DCTH could start receiving increased attention from the street at anytime. Anyone that discover DCTH before the public at large, and before the company’s phase 3 clinical trial could witness a massive uptrend.
These innovative companies deserve your immediate attention:
Delcath Systems, Inc. (OTCQB: DCTH), Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA),
Aphria, Inc. (OTCQX: APHQF), CV Sciences, Inc. (CVSI), and MedMen Enterprises, Inc. (OTCQX: MMNFF)
Delcath Systems, Inc. (OTCQB: DCTH)
Market Cap: $1.77M, Current share price: $1.90
Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on interventional oncology treatment of primary and metastatic liver cancers. Their innovative therapy includes Melphalan Hydrochloride for injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS), which is designed to isolate the liver circulation, deliver a high concentration of chemotherapy (melphalan), and filter most chemotherapy out of the blood prior to returning it to the patient’s body.
Delcath has commenced a global registration trial (The FOCUS Trial) for Patients with Hepatic Dominant Ocular Melanoma (OM) and have initiated a global Phase 3 trial (The ALIGN Trial) for patients with intrahepatic cholangiocarcinoma (ICC).
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA)
Market Cap: $1.767B Share Price: $91.21
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that two of the company’s abstracts have been approved to presentation at the 11th International Respiratory Syncytial Virus Symposium. The Company’s stock has been climbing steadily for the last couple of years, and in recent months even experienced a healthy pullback. Keep an eye on this company.
Aphria Inc. (OTCQX:APHQF)
Market Cap: $3.278B Share Price: $14.03
Aphria Inc., is one of the lowest cost producers, produces, supplies and sells medical cannabis in all of Canada. Aphria is powered by sunlight, allowing for the most natural growing conditions available. The company’s stock has more than doubled in the last month. This has all the looks of a very robust cannabis company.
CV Sciences, Inc. (CVSI)
Market Cap: $379.9M Share Price: $4.19
CV Sciences, Inc. a life science company that plans to operate with two separate divisions, specialty pharmaceuticals and consumer products. The Company is focusing on developing and commercializing prescription drugs utilizing synthetic (CBD). The company’s stock has fallen considerably from recent highs due to class action lawsuits filed by several law firms. The negative press from these suits won’t last forever as we see it and CVSI will be a billion dollar company very soon.
MedMen Enterprises, Inc. (OTCQX: MMNFF)
Market Cap: $1.761B Share Price: 4.26
MedMen Enterprises claims to be the preeminent cannabis company in the United States. The company has assets and operations in California, Nevada, New York and Florida. MedMen owns and operates licensed cannabis facilities cultivation, manufacturing, and retail. The company also claims to be one of the most well recognized cannabis brands in the world today.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns Microcapspeculators.com, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] Microcapspeculators.com does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns Microcapspeculators.com, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and one thousand dollars total by Regal Consulting, LLC, for DCTH. DCTH and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.
For Full Legal Disclaimer Click Here.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States